We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Teva, AZ Want Nexium Conspiracy Lawsuit Tossed

Teva, AZ Want Nexium Conspiracy Lawsuit Tossed

September 3, 2014

Teva and AstraZeneca want a consolidated class action lawsuit alleging they conspired to delay generic entry of AstraZeneca’s acid-reflux drug Nexium dismissed, arguing that Teva couldn’t have marketed its version sooner due to approval delays plaguing Ranbaxy, which has 180 days of generic exclusivity on the product.

The class action lawsuit alleges that AstraZeneca paid off Teva under the guise of a 2010 deal to settle Teva’s patent challenge against Nexium (esomeprazole magnesium). The plaintiffs, comprised of drug distributors, retailers and union health benefit funds, also are suing Ranbaxy and Dr. Reddy’s for similar alleged deals. Plaintiffs say those deals guaranteed no Nexium generic would arrive until May 27 of this year, which forced them to purchase the more expensive branded version for years more than they otherwise would have.

In a dismissal brief filed in Massachusetts federal court, AstraZeneca and Teva rely on recent rulings from the court to argue that generic market entry sooner would have been impossible.

They cite findings that Ranbaxy was entitled to 180-day generic exclusivity as the first-to-file an ANDA against Nexium, but was unable to launch before its licensed-entry date of May 27 because of “continuing, and well-documented difficulties with obtaining FDA approval.”

Ranbaxy’s biggest difficulty has been import bans on all five of its Indian manufacturing facilities. The company still has not entered the market with a generic Nexium product despite the passage of the May 27 entry date, Teva and AstraZeneca said.

AstraZeneca remains the only pharmaceutical company authorized to market Nexium’s active ingredient, according to the Orange Book.

By law, none of the other ANDA filers can get final FDA approval and launch until Ranbaxy does, AstraZeneca and Teva said. Nor is that exclusivity in danger until at least Sept. 30 due to Ranbaxy’s consent decree with the FDA that gave it until then to reach certain milestones, they added. — Bryan Koenig

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Commercial Operations

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing